The breast cancer is a disease that affects mostly women and that in the case of the male population it is very rare -represents 1% of breast tumors-, so many of the decisions and strategies in cancer diagnosis and treatment are carried out based on clinical trials and scientific studies carried out in the female population.
In order to study and learn more about the effects of breast cancer in men, as well as its therapeutic alternatives and its health results, professionals from the Medical Oncology service of the Puerta del Mar Hospital in Cádiz have carried out a study which has determined that the male population analyzed with this type of tumor has worse survival and worse results in the efficacy of treatments.
According to the conclusions of the study, the clinicopathological characteristics of breast cancer in men do not differ significantly from those of women, however, worse health outcomes were observed due to greater comorbidity with other pathologies or health problems and the age at diagnosis of the tumor (they had a median of 64 years).
The descriptive and observational study with data from the Puerta del Mar Hospital, included the analysis of medical records, clinical-pathological data and treatments, events in terms of recurrence (relapse), metastasis, death and survival, of a total of 1,486 cases of breast cancer between 2000 and 2019 in the Cadiz center, of which 16 (1.07%) corresponded to men.
Among these breast tumors in men, 9 cases were confined to the breast, 6 had lymph node involvement, and 1 had metastasis at diagnosis. For its part, the median tumor size was 2.1 cm and only a single BRCA2 + case was found in 6 patients tested for BRCA 1 and 2 genes.
The results of the investigation, which has been presented at the VIII Congress of the Andalusian Society of Medical Oncology (SAOM), held a few days ago in Malaga, also pointed out that 100% of the patients underwent mastectomy as the main route of treatment. Of the 15 patients without cancer metastases, 14 received hormone therapy with tamoxifen and anthracycline / taxane chemotherapy, and 11 also required adjuvant radiation therapy.
Male patients were analyzed during a median follow-up of 60.5 months, during which two suffered locoregional recurrence and four metastases. 31.25% of men died, 60% of them from breast cancer itself. Regarding survival, the mean overall survival was 99 months, while disease-free survival reached 87 months. lower figures than in the case of women with this type of tumor. The authors pointed out that the study has its limitations due to the small size of the sample, but “it is interesting because it makes us reflect on the improvements that early diagnosis with mammography entails in women and the worse prognosis that it causes, not only the more severe diagnosis. advanced, but also the greater age and the greater number of associated diseases in men “.
VIII Congress of the SAOM
The study of the professionals of the Puerta del Mar University Hospital in Cádiz has been one of the outstanding investigations of the VIII Congress of the Andalusian Society of Medical Oncology (SAOM), in which some 300 experts and professionals of medical oncology from all over Andalusia participated appointment at the beginning of November in Malaga to analyze and share the latest strategies for early diagnosis and treatment of cancer, as well as the news in some of the tumors with the greatest impact in the Andalusian population, and other issues to improve the integrated care of cancer patients.
The meeting served to present the results obtained in new personalized cancer treatment strategies, such as immunotherapy, new target molecules and therapies, or other advanced drugs, which are allowing to increase patient survival and improve their quality of life. In addition, it addressed other aspects such as the challenges of precision oncology, the reduction of times from scientific evidence to clinical practice, the current situation of undergraduate oncology teaching or the presentation of the new cancer strategy in Andalusia.
The meeting program included presentations, round tables and sessions with experts articulated around several thematic areas, in which cases of different types of tumors have been presented, such as breast cancer, lung cancer and other thoracic tumors, rare digestive tumors , bladder, or non-melanoma skin tumors. In addition, two round tables were held on the new molecular committees, a key piece in precision oncology that will be developed in the coming years, and on the training plan for resident physicians, where the objectives and realities of the the training of future Andalusian oncologists.